Novacyt

Novacyt EPS Growth

The EPS Growth of Novacyt (ALNOV.PA) as of Nov 3, 2026 is 44.18 %. In the previous year, EPS Growth was -47.60 % — a change of -192.81% (higher).

EPS Growth

44.18 %

YoY

-192.81%

Last updated:

EPS Growth of Novacyt is 2025 44.18 % . EPS Growth of Novacyt was 2024 -47.60 % . It decreases by -192.81% higher compared to the previous year.

The Novacyt EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
35.25 GBP
Jan 1, 2019
-3.25 GBP
Jan 1, 2020
1,808.15 GBP
Jan 1, 2021
-107.35 GBP
Jan 1, 2022
-164.49 GBP
Jan 1, 2023
-9.96 GBP
Jan 1, 2024
-47.60 GBP
Jan 1, 2025
44.18 GBP
The Novacyt EPS Growth history
YEAREPS GrowthYoY
44.18 %-192.81%
-47.60 %+378.01%
-9.96 %-93.95%
-164.49 %+53.24%
-107.35 %-105.94%
1,808.15 %-55,756.81%
-3.25 %-109.22%
35.25 %-23.40%
46.02 %-38.65%
75.01 %-507.81%
-18.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

EPS Growth of Novacyt is 44.18 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Novacyt since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Novacyt historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Novacyt

All Key Metrics — Novacyt